Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Immunology 9, 387 (1 June 2009) | doi:10.1038/nri2579
Cladribine hope for multiple sclerosis
Abstract
Clinical trial results announced at the 61st annual meeting of the American Academy of Neurology suggest that the immunosuppressant drug cladribine (Leustatin, Ortho Biotech; marketed for the treatment of leukaemia) could be a new therapy for patients with multiple sclerosis. The Phase III CLARITY (CLAdRIbine Tablets in treating multiple sclerosis orallY) clinical trial conducted by Merck Serono involved 1,326 patients with relapsing-remitting multiple sclerosis over 2 years who were given two or four treatment courses per year.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
